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:   Long non-coding RNA
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:   Overall Survival
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:   Relapse-Free Survival
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:   Least Absolute Shrinkage and Selection Operation
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:   Receiver Operating Characteristic
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:   Area Under Curve
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:   The Cancer Genome Atlas

MIBC

:   Muscle-Invasive Bladder Cancer

INTRODUCTION
============

Bladder cancer (BLCA) is the ninth most common malignant cancer with high incidence and recurrence rates \[[@r1], [@r2]\]. The risk evaluation of prognosis and recurrence has a critical impact on clinical decision and patient consultation \[[@r3]\]. The most significant factors involved in this evaluation include general condition of patients, clinicopathological characteristics, clinical treatment and progression of disease \[[@r1], [@r4], [@r5]\]. Additionally, tumor node metastasis (TNM) staging system, is currently applied in clinical work as the most common prediction tool \[[@r4], [@r6]\]. Nevertheless, this single clinical prediction model is considered less accurate at prediction than models merging several clinical characteristics \[[@r7]\]. Moreover, the current clinical prediction model cannot facilely incorporate novel factors, such as molecular biomarkers and complex external environmental factors \[[@r5]\].

Over the years, scientists have proposed numerous potential molecular signatures as predictors of the risk of cancer progression, with the most important of them being the DNA methylation-based models \[[@r8]--[@r10]\], mRNA \[[@r11], [@r12]\], microRNA(miRNA) \[[@r13]\] and long non-coding RNA (lncRNA)-based models \[[@r14], [@r15]\]. Increasing evidence has indicated the critical role of lncRNAs in BLCA prognosis and recurrence, being involved in cancer initiation, progression and metastasis \[[@r16]\]. However, the prognostic value of lncRNAs in BLCA has not been adequately explored yet.

In this study, in an effort to assess the potential utility of lncRNAs in prognosis and recurrence of BLCA, we constructed a 14-lncRNA-based classifier for overall survival (OS) and a 12-lncRNA-based classifier for relapse-free survival (RFS) by using the least absolute shrinkage and selection operation (LASSO) Cox regression. Both of the lncRNA-based classifiers could optimize the predictivity of the current TNM staging system. Our results demonstrate that these lncRNA-based classifiers could be used as reliable prognostic predictors of BLCA survival and recurrence.

RESULTS
=======

Data source and processing
--------------------------

The lncRNA expression profiles in BLCA tissues (n=414) along with the adjacent non-tumor tissues (n=19) were obtained from the TCGA database. As shown in [Figure 1](#f1){ref-type="fig"}, a total of 1643 DElncRNAs ([Figure 2A](#f2){ref-type="fig"}) with \|logFC\| \>1 and padj \< 0.05 were identified using edgeR. Additionally, lncRNAs with *p* \< 0.05 were chosen by applying a univariate Cox regression in the entire data. Following this, 463 lncRNAs (OS, [Figure 2B](#f2){ref-type="fig"}) and 201 lncRNAs (RFS, [Figure 2C](#f2){ref-type="fig"}) were retained for the next step of the analysis. For OS, these samples (n=406) were randomly split into training (n=271) and validation sets (n=135) at 2:1 ratio. Similarly, for RFS, the samples (n=337) were randomly split into training (n=225) and validation sets (n=112) at a 2:1 ratio. The LASSO Cox selection method was applied to construct the prognosis-predicting models in the training cohort at a 20-fold cross-validation (OS: [Figure 2D](#f2){ref-type="fig"}, [2E](#f2){ref-type="fig"}; RFS: [Figure 2F](#f2){ref-type="fig"}, [2G](#f2){ref-type="fig"}).

![**Study flowchart showing steps involved in construction of lncRNA-based prognostic signatures.**](aging-11-102185-g001){#f1}

![(**A**) Volcano plot of differentially expressed lncRNAs in TCGA-BLCA cohort. (**B** and **C**) Venn diagram of prognostic DElncRNAs in prognostic lncRNAs (OS/RFS univariate cox p \< 0.05) and DElncRNAs(\|logFC\| \>1 and padj \< 0.05). (**D**) 20-time cross-validation for tuning parameter selection in the LASSO model for OS. (**E**) LASSO coefficient profiles of 463 prognostic DElncRNAs for OS. (**F**) 20-time cross-validation for tuning parameter selection in the LASSO model for RFS. (**G**) LASSO coefficient profiles of 201 prognostic DElncRNAs for RFS.](aging-11-102185-g002){#f2}

Construction of lncRNAs classifiers for OS and RFS
--------------------------------------------------

In the training cohort, a 14-lncRNA-based classifier for OS and a 12-lncRNA-based classifier for RFS were constructed using the LASSO Cox regression mode at 20-fold cross-validation. Detailed information of these lncRNAs is shown in [Table 1](#t1){ref-type="table"}. According to the prediction value, patients were divided into high- and low-risk groups based on the cut-off of the median risk score. The Kaplan--Meier log-rank test showed significant differences in OS and RFS between low- and high-risk groups in the training cohorts ([Figure 3A](#f3){ref-type="fig"}, [3B](#f3){ref-type="fig"}), the validation cohorts ([Figure 3C](#f3){ref-type="fig"}, [3D](#f3){ref-type="fig"}) and in the whole cohorts ([Figure 3E](#f3){ref-type="fig"}, [3F](#f3){ref-type="fig"}).

###### The detailed information of lncRNAs for constructing the prognostic signature.

  ---------------------------------------- ------------------- ---------------- --------------------- ------------------- -------------
  **14-lncRNA-based classifier for OS**                                                                                   
  **Gene name**                            **ENSG_ID**         **Chromosome**   **Gene start (bp)**   **Gene end (bp)**   **β**
  AL662844.4                               ENSG00000272501.1   6p21.33          31195200              31198037            0.000859567
  MAFG-AS1                                 ENSG00000265688     17q25.3          81927829              81930753            0.00024963
  RNF144A-AS1                              ENSG00000228203     2p25.1           6918682               6912276             0.00135716
  AC093788.1                               ENSG00000273449     4q32.2           163529771             163530697           0.001168141
  AC024060.1                               ENSG00000271870     3p26.2           3152942               3153435             0.000445531
  LINC01138                                ENSG00000274020     1q21.2           148459920             148432959           0.000350856
  Z84484.1                                 ENSG00000224666     6p21.31          36386831              36393462            0.002095112
  MANCR                                    ENSG00000231298     10p15.1          4650185               4678154             0.000322206
  AL590428.1                               ENSG00000231652     6q13             73693903              73696131            0.004351042
  CERS3-AS1                                ENSG00000259430     15q26.3          100372939             100437914           0.003812687
  AL590999.1                               ENSG00000235033     6p21.2           39881804              39900071            0.000167192
  Z98200.1                                 ENSG00000271734     6q21             108030249             108030718           0.003081411
  LINC01169                                ENSG00000259471     15q22.31         66582190              66685798            0.002831088
  AL049775.1                               ENSG00000205562     14q31.3          85530313              85522055            0.002947469
  **12-lncRNA-based classifier for RFS**                                                                                  
  **Gene name**                            **ENSG_ID**         **Chromosome**   **Gene start (bp)**   **Gene end (bp)**   **β**
  NALCN-AS1                                ENSG00000233009     13q32.3          100708325             101059286           0.003081179
  AL353593.2                               ENSG00000269934     1q42.13          228274584             228276066           0.007001554
  AC116914.2                               ENSG00000262692     17p13.2          3721628               3722488             0.000160626
  AC092910.3                               ENSG00000242622     3q13.33          120094895             120136783           0.00432904
  FLJ22447                                 ENSG00000232774     14q23.1          61570540              61658696            0.000201789
  SH3RF3-AS1                               ENSG00000259863     2q13             109127327             109128930           0.006699057
  AL121658.1                               ENSG00000272716     2p22.3           32165046              32165757            0.005552396
  AL590428.1                               ENSG00000231652     6q13             73693903              73696131            0.003681168
  AC080013.3                               ENSG00000271778     3q25.32          158782547             158783124           0.001601851
  LSAMP-AS1                                ENSG00000240922     3q13.31          116360024             116370090           0.011192555
  SLC26A4-AS1                              ENSG00000233705     7q22.3           107653968             107662151           0.002233053
  AC023051.1                               ENSG00000234428     12p11.23         26623369              26649479            0.011428433
  ---------------------------------------- ------------------- ---------------- --------------------- ------------------- -------------

![(**A**, **C** and **E**) Overall survival curves of BLCA patients in training, validation and all cohorts with a low or high risk of death, according to 14-lncRNA-based classifier risk score level. (**B**, **D** and **F**): Relapse-free survival curves of BLCA patients in training, validation and all cohorts with a low or high risk of death, according to 12-lncRNA-based classifier risk score level.](aging-11-102185-g003){#f3}

Correlation between lncRNAs classifiers and clinicopathologic characteristics
-----------------------------------------------------------------------------

There were no significant difference and deviation between the training cohort and the validation cohort, because these samples were randomly split into training and validation sets at a 2:1 ratio in [Tables 2](#t2){ref-type="table"}--[5](#t5){ref-type="table"}. As shown in [Table 2](#t2){ref-type="table"}, for OS, the clinical characteristics (subtype, pT, pN and grade) showed significant differences between the two groups in whole cohort. However, for RFS, many clinical characteristics, except pT, did not vary significantly between the two groups in whole cohort ([Table 3](#t3){ref-type="table"}). Though the lncRNA-based risk scores of OS or RFS were independent of several clinical characteristics, positive associations were detected between them ([Figure 4](#f4){ref-type="fig"}). Patients with high pT, pN or grade were inclined to have a high-risk score.

###### Correlations between risk score of the 14-marker-based classifier with OS and clinicopathological characteristics in training cohort, validation cohort and whole cohort.

  ------------------- --------------- -------------- ------------------ --------------
  **Parameters**      **High risk**   **Low risk**   **Pearson *x*2**   **P**
  Training cohort                                                       
   Age                                               0.06006            0.8064
   \>60               102             101                               
   ≤60                33              35                                
   Gender                                            1.336519           0.247649
   male               97              106                               
   female             38              30                                
  --Subtype                                          6.471522           **0.010962**
   Papillary          37              58                                
   Non-Papillary      96              78                                
   pT                                                4.199471           **0.040437**
   T3-4               93              75                                
   T0-2               35              49                                
   pN                                                0.411615           0.521151
   N1-3               39              35                                
   N0                 82              88                                
   pM                                                1.633899           0.502242
   M1                 0               2                                 
   M0                 62              75                                
   Grade                                             6.48751            **0.010864**
   high               131             3                                 
   low                123             13                                
  Validation cohort                                                     
   Age                                               0.141667           0.70663
   \>60               49              47                                
   ≤60                19              21                                
   Gender                                            1.314715           0.251543
   male               46              52                                
   female             22              16                                
   Subtype                                           8.421529           **0.003708**
   Papillary          10              25                                
   Non-Papillary      56              42                                
   pT                                                3.986205           **0.045874**
   T3-4               48              35                                
   T0-2               15              24                                
   pN                                                9.125692           **0.00252**
   N1-3               36              19                                
   N0                 25              41                                
   pM                                                2.92108            0.087429
   M1                 6               3                                 
   M0                 22              38                                
   Grade                                             5.193798           **0.022668**
   high               67              62                                
   low                0               5                                 
  Whole cohort                                                          
   Age                                               0.317257           0.573261
   \>60               152             147                               
   ≤60                51              56                                
   Gender                                            2.50239            0.113674
   male               143             157                               
   female             60              46                                
   Subtype                                           15.606417          **0.000078**
   Papillary          46              84                                
   Non-Papillary      153             118                               
   pT                                                7.172964           **0.007401**
   T3-4               142             109                               
   T0-2               51              71                                
   pN                                                5.465341           **0.019397**
   N1-3               75              53                                
   N0                 108             128                               
   pM                                                0.579021           0.537858
   M1                 6               5                                 
   M0                 84              112                               
   Grade                                             11.224962          **0.000807**
   high               198             184                               
   low                3               18                                
  ------------------- --------------- -------------- ------------------ --------------

###### Correlations between risk score of the 12-marker-based classifier with RFS and clinicopathological characteristics in training cohort, validation cohort and whole cohort.

  ------------------- --------------- -------------- ------------------ -------------
  **Parameters**      **High risk**   **Low risk**   **Pearson *x*2**   **P**
  Training cohort                                                       
   Age                                               0.421              0.516
   \>60               81              86                                
   ≤60                31              27                                
   Gender                                            1.052              0.305
   male               86              93                                
   female             26              20                                
   Subtype                                           0.880              0.348
   Papillary          34              42                                
   Non-Papillary      75              71                                
   pT                                                3.823              0.0506
   T3-4               72              64                                
   T0-2               27              43                                
   pN                                                2.379              0.123
   N1-3               36              25                                
   N0                 69              77                                
   pM                                                0.4292             0.685
   M1                 4               2                                 
   M0                 62              55                                
   Grade                                             0.000255           0.987
   high               105             106                               
   low                6               6                                 
  Validation cohort                                                     
   Age                                               0.175              0.676
   \>60               39              41                                
   ≤60                17              15                                
   Gender                                            0.676              0.411
   male               37              41                                
   female             19              15                                
   Subtype                                           0.00433            0.948
   Papillary          18              18                                
   Non-Papillary      38              37                                
   pT                                                7.104              **0.00769**
   T3-4               37              24                                
   T0-2               13              26                                
   pN                                                0.0504             0.822
   N1-3               14              15                                
   N0                 32              31                                
   pM                                                0.390              0.611
   M1                 2               1                                 
   M0                 26              28                                
   Grade                                             0.578              0.489
   high               53              50                                
   low                3               5                                 
  Whole cohort                                                          
   Age                                               0.595              0.440
   \>60               120             127                               
   ≤60                48              42                                
   Gender                                            0.638              0.425
   male               125             132                               
   female             43              37                                
   Subtype                                           0.658              0.417
   Papillary          52              60                                
   Non-Papillary      113             108                               
   pT                                                8.317              **0.00393**
   T3-4               108             89                                
   T0-2               41              68                                
   pN                                                0.801              0.371
   N1-3               49              41                                
   N0                 102             107                               
   pM                                                0.0421             0.837
   M1                 5               4                                 
   M0                 89              82                                
   Grade                                             0.213              0.645
   high               158             156                               
   low                9               11                                
  ------------------- --------------- -------------- ------------------ -------------

![Boxplot of risk score in patients with pT (**A**, OS), pN (**B**, OS), grade (**C**, OS) and pT (**D**, RFS).](aging-11-102185-g004){#f4}

Prognostic value of lncRNAs classifiers for assessing clinical outcome
----------------------------------------------------------------------

In the time-dependent ROC curve analysis, the AUCs for OS ([Figure 5A](#f5){ref-type="fig"}) in the first, third, and fifth year were 0.734, 0.78, and 0.78 respectively, while the prediction capability of the 14-lncRNA classifier was superior to the previously published lncRNA classifier \[[@r17]\]. As for RFS ([Figure 5B](#f5){ref-type="fig"}), the AUCs in the first, third, and fifth year were 0.755, 0.715, and 0.740 respectively, whilst the 12-lncRNA-based classifier was mainly built to be a powerful prognostic predictor of BLCA recurrence. As shown in [Table 4](#t4){ref-type="table"}, the 14-marker-based classifier, age, pT, pN and pM were significantly associated with OS in the univariate Cox regression analyses. After the multivariate Cox regression analyses of the above-mentioned factors, only the 14-marker-based classifier model was retained to be a dependable and independent prognostic factor for OS (*p* \< 0.001) in whole cohort. In univariate Cox regression analyses, the 12-marker- based classifier, subtype, pT, pN and pM were significantly associated with RFS in [Table 5](#t5){ref-type="table"}. Finally, the multivariate Cox regression analyses revealed that only the 12-marker-based classifier model could be a novel and independent prognostic factor for RFS (*p*= 0.001) in whole cohort.

![(**A** and **B**) Time dependent ROC curves at 1, 3 and 5 years, separately for OS and RFS. (**C** and **D**) The ROC for the lncRNA-score, stage, and lncRNA-score combined with stage for OS and RFS in whole BLCA cohorts. (**E** and **F**) Survival curves of BLCA patients with combinations of lncRNA-score risk and stage in the whole cohorts for OS and RFS.](aging-11-102185-g005){#f5}

###### Univariate and multivariate Cox regression analysis of the 14-marker-based classifier with OS in training cohort, validation cohort and whole cohort.

  ----------------------------------------------------- ------------------------- ---------------------- --------------------- --------------
  **Parameters**                                        **Univariate COX**        **Multivariate COX**                         
  **HR (95% CI)**                                       **P**                     **HR (95% CI)**        **P**                 
  Training cohort                                                                                                              
   Age (\>60 vs ≤60)                                    1.506(0.937,2.421)        0.090459               0.910(0.399,2.076)    0.823185
   Gender(male vs female)                               0.934(0.620,1.406)        0.742189                                     
   Subtype (Papillary vs Non-Papillary)                 0.780(0.512,1.189)        0.248073               1.043(0.508,2.142)    0.909174
   pT (T3-4 vs T0-2)                                    1.654(1.066,2.564)        **0.024634**           1.269(0.513,3.138)    0.605957
   pN (N1-3 vs N0)                                      2.153(1.451,3.196)        **1.41E-04**           1.599(0.834,3.066)    0.157505
   pM (M1 vs M0)                                        1.969(0.270,14.378)       0.504059                                     
   Grade(high vs low)                                   1.998(0.491,8.129)        0.333785                                     
   14-marker-based classifier (high risk vs low risk)   3.994(2.629,6.068)        **8.66E-11**           5.215(2.502,10.869)   **0.00001**
  Validation cohort                                                                                                            
   Age (\>60 vs ≤60)                                    3.135(1.595,6.165)        **0.000923**           2.766(1.286,5.948)    **0.009202**
   Gender(male vs female)                               0.755(0.442,1.291)        0.30446                                      
   Subtype (Papillary vs Non-Papillary)                 0.463(0.236,0.911)        **0.025825**           0.706(0.325,1.533)    0.378535
   pT (T3-4 vs T0-2)                                    4.020(1.904,8.487)        **0.000264**           3.014(1.222,7.433)    **0.016621**
   pN (N1-3 vs N0)                                      2.338(1.352,4.042)        **2.37E-03**           1.218(0.664,2.236)    0.523547
   pM (M1 vs M0)                                        4.864(1.961,12.066)       0.000642                                     
   Grade(high vs low)                                   21.188(0.019,23176.048)   0.39241                                      
   14-marker-based classifier (high risk vs low risk)   2.588(1.526,4.387)        **4.16E-04**           2.005(1.091,3.685)    **0.025003**
  Whole cohort                                                                                                                 
   Age (\>60 vs ≤60)                                    1.897(1.287,2.794)        **0.001206**           1.604(0.799,3.223)    0.184
   Gender(male vs female)                               0.88(0.635,1.217)         0.439                                        
   Subtype (Papillary vs Non-Papillary)                 0.655(0.459,0.933)        **0.018962**           0.992(0.541,1.82)     0.98
   pT (T3-4 vs T0-2)                                    2.14(1.472,3.111)         **0.000067**           1.489(0.745,2.978)    0.26
   pN (N1-3 vs N0)                                      2.268(1.656,3.105)        **3.29E-07**           1.248(0.718,2.17)     0.432
   pM (M1 vs M0)                                        3.305(1.579,6.915)        **0.001507**           1.612(0.589,4.413)    0.352
   Grade(high vs low)                                   2.926(0.724,11.829)       0.131854                                     
   14-marker-based classifier (high risk vs low risk)   3.526(2.537,4.901)        **6.26E-14**           3.976(2.192,7.211)    **6.00E-06**
  ----------------------------------------------------- ------------------------- ---------------------- --------------------- --------------

###### Univariate and multivariate Cox regression analysis of the 12-marker-based classifier with RFS in training cohort, validation cohort and whole cohort.

  ----------------------------------------------------- ------------------------- ---------------------- ------------------------- --------------
  **Parameters**                                        **Univariate COX**        **Multivariate COX**                             
  **HR (95% CI)**                                       **P**                     **HR (95% CI)**        **P**                     
  Training cohort                                                                                                                  
   Age (\>60 vs ≤60)                                    2.055(1.005,4.202)        **0.048360973**        1.239(0.451,3.404)        0.678047
   Gender(male vs female)                               0.880(0.454,1.707)        0.704943796                                      
   Subtype (Papillary vs Non-Papillary)                 1.357(0.733,2.510)        0.331186056                                      
   pT (T3-4 vs T0-2)                                    2.337(1.166,4.685)        **0.016743034**        1.636(0.635,4.212)        0.307782
   pN (N1-3 vs N0)                                      2.576(1.482,4.477)        **0.00079688**         1.467(0.624,3.449)        0.379187
   M (M1 vs M0)                                         6.003(1.757,20.512)       **0.004255841**        3.330(0.384,28.905)       0.275237
   Grade(high vs low)                                   2.135(0.294,15.528)       0.453562546                                      
   12-marker-based classifier (high risk vs low risk)   5.607(2.885,10.898)       **0.000000368**        3.364(1.349,8.384)        **0.00924**
   Validation cohort                                                                                                               
   Age (\>60 vs ≤60)                                    0.581(0.286,1.180)        0.133271407                                      
   Gender(male vs female)                               1.124(0.527,2.399)        0.761624713                                      
   Subtype (Papillary vs Non-Papillary)                 0.341(0.130,0.891)        **0.028126777**        0.492(0.099,2.437)        0.384909
   pT (T3-4 vs T0-2)                                    2.379(1.003,5.646)        **0.049252702**        34614.538(0,4.777E+157)   0.953672
   pN (N1-3 vs N0)                                      2.792(1.227,6.352)        **0.014351444**        1.644(0.433,6.247)        0.466
   M (M1 vs M0)                                         6.121(0.684,54.771)       0.105160081            4.189(0.334,52.541)       0.26697
   Grade(high vs low)                                   22.506(0.029,17274.179)   0.35827                                          
   12-marker-based classifier (high risk vs low risk)   2.941(1.353,6.394)        **0.006477803**        9.857(1.212,80.2)         **0.032403**
  Whole cohort                                                                                                                     
   Age (\>60 vs ≤60)                                    1.168(0.724,1.883)        0.525022                                         
   Gender(male vs female)                               0.986(0.603,1.614)        0.956337                                         
   Subtype (Papillary vs Non-Papillary)                 0.58(0.346,0.969)         **0.038**              0.694(0.322,1.494)        0.351
   pT (T3-4 vs T0-2)                                    2.319(1.351,3.981)        **0.00229**            1.835(0.661,5.095)        0.244
   pN (N1-3 vs N0)                                      2.647(1.681,4.17)         **0.000027**           1.537(0.769,3.072)        0.224
   M (M1 vs M0)                                         5.815(2.003,16.885)       **0.001208**           3.808(0.809,17.927)       0.091
   Grade(high vs low)                                   4.044(0.561,29.136)       0.165449                                         
   12-marker-based classifier (high risk vs low risk)   4.212(2.552,6.953)        **1.88E-08**           3.816(1.698,8.571)        **0.001**
  ----------------------------------------------------- ------------------------- ---------------------- ------------------------- --------------

In clinical practice, the most commonly used risk classification is TNM staging. Therefore, the association between the lncRNA-based classifier models and TNM staging was explored. The ROC curve analysis compared TNM staging with the lncRNA-based classifier models which had an obvious better predictive accuracy. The results indicated that the combination of the lncRNA-based classifier models and TNM staging could enhance the ability to predict prognosis of survival and recurrence ([Figure 5C](#f5){ref-type="fig"}, [5D](#f5){ref-type="fig"}). The Kaplan--Meier curves revealed that patients separated by combining the lncRNA-based risk scores and TNM staging had evidently discrepant prognoses (*p*\< 0.0001, [Figure 5E](#f5){ref-type="fig"}, [5F](#f5){ref-type="fig"}).

DISCUSSION
==========

Patients with BLCA, especially muscle-invasive bladder cancer (MIBC), still have significant risks of relapse and death, in spite of radical cystectomy \[[@r4], [@r6], [@r18], [@r19]\]. To a certain extent, the aggressiveness of BLCA cannot be accurately stratified by the TNM staging system, which mostly depends on the pathological staging without any molecular biological features \[[@r20], [@r21]\]. On that account, finding new and effective prognostic biomarkers is critical for patients with MIBC due to the disappointing clinical outcomes.

Increasing evidence has demonstrated that dysregulated lncRNAs may contribute to cancer initiation, progression and metastasis \[[@r22]\]. Several lncRNA-based signatures have been applied to predict the risk of cancer progression in patients with different cancer types, such as renal cell carcinoma \[[@r14]\] and colon cancer \[[@r15]\]. As for BLCA, although the prognostic value of lncRNAs has also been explored by some authors \[[@r17], [@r23]\], there are still many things to be improved. The reasons for this are the following: (1) the internal validation dataset is needed to validate the stability of the constructed model; (2) the comparison between the constructed model and the existing TNM staging system is indispensable; (3) the prognostic value of BLCA recurrence should be further explored. Therefore, in this study, based on a TCGA-BLCA cohort, we established and validated novel prognostic lncRNA-based signatures for OS and RFS, in order to improve the prediction of mortality and disease recurrence. The LASSO-Cox regression mode, as a popular tool for regression with high-dimensional predictors, has previously been performed in the study of colon cancer but has not been applied yet to the study of BLCA. Thus, in this study, the LASSO-Cox regression mode was applied as an effort to optimally select lncRNAs with high expression variances, significant prognostic values and low correlation by using LASSO penalization. A 14-lncRNA-based classifier for OS and a 12-lncRNA-based classifier for RFS were constructed and validated to optimize the predictive ability of prognosis for BLCA patients. The results indicated that the two classifiers could successfully divide BLCA patients into high/low-risk groups with significant differences in OS and RFS in training cohorts. The prognostic value of the two classifiers could be confirmed in validation cohorts, indicating the repeatability and practicability of the two lncRNA-based classifiers for the prognostic prediction for OS and RFS. As shown in [Table 2](#t2){ref-type="table"} and [Table 3](#t3){ref-type="table"}, the 14-marker-based classifier, age, pT, pN and pM were significantly associated with OS, while the 12-marker-based classifier, subtype, pT, pN and pM were significantly associated with RFS in univariate Cox regression analyses. In multivariate Cox regression analyses, only the 14-lncRNA-based classifier model was retained to be a dependable and independent prognostic factor for OS (*p* \< 0.001) and only the 12-lncRNA-based classifier model could qualify as a novel and independent prognostic factor for RFS (*p* = 0.001). In clinical practice, the most used risk classification is TNM staging. Next, the association between the lncRNA-based classifier models and TNM staging were explored. In the ROC curve analysis, compared TNM staging, the lncRNA-based classifier models had an obviously better predictive accuracy, and the combination of the lncRNA-based classifier models and TNM staging could enhance the ability to predict prognosis of survival and recurrence. The Kaplan--Meier curves revealed that patients separated by both the lncRNA-based risk scores and TNM staging had evidently discrepant prognoses.

Our study has showed that the 14-lncRNA-based classifier for OS and the 12-lncRNA-based classifier for RFS were both strongly associated with the prognosis of BLCA. However, most of the lncRNAs in our classifiers have not been completely clarified and functionally annotated. On the other hand, several lncRNAs used in our classifiers have been explored in previous studies. MAFG-AS1 has been shown to function as a ceRNA to increase the expression of MMP15 and NDUFA4. It does so by competing for miR-339-5p and miR-147b, thus exerting its oncogenic function in non-small- cell carcinoma \[[@r24]\] and colorectal cancer \[[@r25]\]. LINC01138 induces malignancies via activating arginine methyltransferase 5 and interacting with PRMT5 to promote SREBP1-mediated lipid desaturation individually in hepatocellular carcinoma \[[@r26]\] and clear cell renal cell carcinoma \[[@r27]\]. Given their strong relevance to prognosis, these genes should be explored in the future, especially in relation to BLCA.

Inevitably, the present study has some innate limitations which need to be addressed. Firstly, the current study was of a retrospective nature, since it was based on data from TCGA dataset without validating it in a prospective clinical trial. Secondly, the mechanism behind the lncRNAs in our classifiers remains entirely unclear. Hence, the need for further studies of the specific lncRNAs is indisputable, as they can contribute to a distinct understanding of the implication of lncRNAs in BLCA initiation and progression. Moreover, the information regarding several important clinicopathological features, such as treatments, was not available in the TCGA-BLCA cohort. Despite these drawbacks, the results demonstrate that our lncRNA-based classifiers could be used as reliable prognostic predictors of BLCA survival and recurrence.

In summary, a 14-lncRNA-based classifier for OS and a 12-lncRNA-based classifier for RFS were constructed using the LASSO Cox regression model. These classifiers could be novel and independent prognostic factors for OS and RFS respectively, while optimizing the predictive ability of the current (TNM) staging system. Nevertheless, future, large-scale, multi-center studies are necessary to confirm our results before the lncRNA-based signatures can be applied in the clinic.

MATERIALS AND METHODS
=====================

Patient datasets
----------------

TCGA-BLCA RNA sequencing dataset and corresponding clinical characteristics of patients were downloaded from the TCGA website (<https://cancergenome.nih.gov/>), including 414 BLCA tissues and 19 adjacent non-tumor tissues. The RFS data was downloaded from the UCSC Xena website (<https://xena.ucsc.edu/>). We excluded the lncRNA whose expression (read counts) was "zero" in 90% of the BLCA patients.

Data processing
---------------

BLCA data were annotated by Gencode (GENCODE v 26) GTF file in this study. As shown in [Figure 1](#f1){ref-type="fig"}, we used edgeR for the entire data in order to identify the differentially expressed lncRNAs(DElncRNAs) with \|logFC\| \>1 and padj \< 0.05 between tumor and normal samples. Meanwhile, we conducted a univariate Cox regression for all lncRNAs in cancer samples and chose the lncRNAs with *p* \< 0.05 for the next analysis. The DElncRNAs with \|logFC\| \>1 and padj \< 0.05 were retained to determine their overlap with lncRNAs with *p* \< 0.05 in the univariate Cox regression. Afterwards, these samples were randomly split into training and validation sets at a 2:1 ratio. Following this, we applied the LASSO Cox selection method at 20-fold cross-validation to construct the survival-predicting models. The predictive ability of the model for the training, validation and whole cohorts were evaluated by the Kaplan--Meier log-rank test, Time-dependent ROC curve analysis and multivariate Cox regression analysis.

Construction of lncRNAs signature and statistical analysis
----------------------------------------------------------

The lncRNAs-based prognosis risk score was constructed based on a linear combination of the expression level multiplied regression model (β) and the LASSO Cox selection method \[[@r28]--[@r30]\] at 20-fold cross-validation. Based on the cut-off of the median risk score, BLCA patients were divided into high- and low-risk groups. The Kaplan-Meier survival curves for the cases predicted to have low or high risk were produced. All the analyses were implemented in SPSS version 23.0 or R version 3.5.2 with the following packages: 'edgeR', 'glmnet', 'survivalROC' and 'gplot'. All the hypotheses were two-sided and P \< 0.05 was considered statistically significant.
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